%0 Journal Article %1 Deubner2010 %A Deubner, N. %A Berliner, D. %A Schlipp, A. %A Gelbrich, G. %A Caforio, A. L. %A Felix, S. B. %A Fu, M. %A Katus, H. %A Angermann, C. E. %A Lohse, M. J. %A Ertl, G. %A Stork, S. %A Jahns, R. %D 2010 %J Eur J Heart Fail %K *Research Antibody Autoantibodies/*immunology Autoimmunity/*immunology Cardiomyopathy, Design Dilated/*immunology Humans Immunoassay/methods Infarction/*immunology Multicenter Myocardial Myocarditis/*immunology Myocardium/*immunology Patient Selection Specificity/immunology Studies Topic as beta-1/*immunology Receptor Adrenergic %N 7 %P 753-62 %T Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study %U http://www.ncbi.nlm.nih.gov/pubmed/20494925 %V 12 %X AIMS: Evidence for a pathophysiologic relevance of autoimmunity in human heart disease has substantially increased over the past years. Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor (beta1-aabs) are considered of importance in heart failure development and clinical pilot studies have shown their prognostic significance in human 'idiopathic' cardiomyopathy. METHODS: We recently developed a novel highly sensitive fluorescence-based functional assay to detect stimulating beta1-aabs. We will use this method to assess Etiology, Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective multicentre study with serial follow-up of patients after a first acute myocarditis or myocardial infarction. Several European core laboratories will jointly study the hypothesis that both disorders may trigger autoimmune reactions leading to the generation of beta1-aabs and/or other heart-directed aabs. Further, sera from healthy controls and well-characterized patient cohorts with dilated, ischaemic, or hypertensive cardiomyopathy will be analysed retrospectively for beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION: ETiCS is so far the largest clinical diagnostic study projected to address cardiac autoimmunity. It attempts to unravel the pathophysiology of cardiac autoantibody formation and persistence/clearance. ETiCS will enhance current knowledge on autoimmunity in human heart disease and promote endeavours to develop novel therapies targeting cardiac aabs.

@article{Deubner2010, abstract = {AIMS: Evidence for a pathophysiologic relevance of autoimmunity in human heart disease has substantially increased over the past years. Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor (beta1-aabs) are considered of importance in heart failure development and clinical pilot studies have shown their prognostic significance in human 'idiopathic' cardiomyopathy. METHODS: We recently developed a novel highly sensitive fluorescence-based functional assay to detect stimulating beta1-aabs. We will use this method to assess Etiology, Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective multicentre study with serial follow-up of patients after a first acute myocarditis or myocardial infarction. Several European core laboratories will jointly study the hypothesis that both disorders may trigger autoimmune reactions leading to the generation of beta1-aabs and/or other heart-directed aabs. Further, sera from healthy controls and well-characterized patient cohorts with dilated, ischaemic, or hypertensive cardiomyopathy will be analysed retrospectively for beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION: ETiCS is so far the largest clinical diagnostic study projected to address cardiac autoimmunity. It attempts to unravel the pathophysiology of cardiac autoantibody formation and persistence/clearance. ETiCS will enhance current knowledge on autoimmunity in human heart disease and promote endeavours to develop novel therapies targeting cardiac aabs.}, added-at = {2010-12-14T18:12:02.000+0100}, author = {Deubner, N. and Berliner, D. and Schlipp, A. and Gelbrich, G. and Caforio, A. L. and Felix, S. B. and Fu, M. and Katus, H. and Angermann, C. E. and Lohse, M. J. and Ertl, G. and Stork, S. and Jahns, R.}, biburl = {https://www.bibsonomy.org/bibtex/2c401fafdb01fa91763c89df711e54c37/pharmawuerz}, endnotereftype = {Journal Article}, groups = {private}, interhash = {aecb0fa66838c96717ef5d45e7625195}, intrahash = {c401fafdb01fa91763c89df711e54c37}, issn = {1879-0844 (Electronic) 1388-9842 (Linking)}, journal = {Eur J Heart Fail}, keywords = {*Research Antibody Autoantibodies/*immunology Autoimmunity/*immunology Cardiomyopathy, Design Dilated/*immunology Humans Immunoassay/methods Infarction/*immunology Multicenter Myocardial Myocarditis/*immunology Myocardium/*immunology Patient Selection Specificity/immunology Studies Topic as beta-1/*immunology Receptor Adrenergic}, month = Jul, note = {Deubner, Nikolas Berliner, Dominik Schlipp, Angela Gelbrich, Gotz Caforio, Alida L P Felix, Stephan B Fu, Michael Katus, Hugo Angermann, Christiane E Lohse, Martin J Ertl, Georg Stork, Stefan Jahns, Roland Etiology, Titre-Course, and Survival-Study Group Research Support, Non-U.S. Gov't Netherlands European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology Eur J Heart Fail. 2010 Jul;12(7):753-62. Epub 2010 May 21.}, number = 7, pages = {753-62}, shorttitle = {Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study}, timestamp = {2010-12-14T18:22:39.000+0100}, title = {Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study}, url = {http://www.ncbi.nlm.nih.gov/pubmed/20494925}, volume = 12, year = 2010 }